Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 3, 2023
Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial
Marc Hilmi, Maud Kamal, Sophie Vacher, et al.
Molecular Cancer Therapeutics
|
February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2011
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
Sandrine Faivre, Magaly Zappa, Valérie Vilgrain, et al.
Breast Cancer Research : BCR
|
January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
British Journal of Cancer
|
August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Marie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
The Lancet. Oncology
|
September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
JCO Precision Oncology
|
September 11, 2020
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial
Clémence Basse, Claire Morel, Céline Callens, et al.
Oncoimmunology
|
September 14, 2016
Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma
Maude Guillot-Delost, Lia Guilleré, Frédérique Berger, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
European Journal of Cancer (Oxford, England : 1990)
|
March 3, 2023
Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial
Marc Hilmi, Maud Kamal, Sophie Vacher, et al.
Molecular Cancer Therapeutics
|
February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2011
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
Sandrine Faivre, Magaly Zappa, Valérie Vilgrain, et al.
Breast Cancer Research : BCR
|
January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
British Journal of Cancer
|
August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Marie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
The Lancet. Oncology
|
September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
JCO Precision Oncology
|
September 11, 2020
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial
Clémence Basse, Claire Morel, Céline Callens, et al.
Oncoimmunology
|
September 14, 2016
Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma
Maude Guillot-Delost, Lia Guilleré, Frédérique Berger, et al.
Page
of 6